Table 2.
Development of PD-MCI considering the 84 PD-NC at baseline.
| Univariate analysis |
Multivariate analysis |
|||||||
|---|---|---|---|---|---|---|---|---|
| PD-MCI N = 28 | PD No-MCI N = 52 | HR | 95%CI | p-value | HR | 95%CI | p-value | |
| Sex, Men (%) | 18 (64.3) | 33 (63.4) | 1.30 | 0.58–2.90 | 0.6 | 0.83 | 0.36–1.96 | 0.7 |
| Age, years | 68.5 ± 9.8 | 62.2 ± 10.3 | 1.04 | 1.00–1.09 | 0.04 | 1.04 | 0.99–1.08 | 0.07 |
| Age ≤ 66 years | 8 (28.6) | 33 (63.5) | 1 | / | / | |||
| Age > 66 years | 20 (71.4) | 19 (36.5) | 2.81 | 1.24–6.41 | 0.01 | |||
| Age at onset, years | 65.2 ± 10.8 | 59.6 ± 11.0 | 1.04 | 1.00–1.08 | 0.06 | |||
| Age at onset ≤ 50 years | 2 (7.1) | 10 (19.2) | 1 | / | / | |||
| Age at onset > 50 years | 26 (92.9) | 42 (80.8) | 2.10 | 0.49–8.99 | 0.3 | |||
| UPDRS-ME | 24.4 ± 13.0 | 24.6 ± 14.2 | 0.98 | 0.95–1.00 | 0.2 | |||
| HY stage | 2.1 ± 0.9 | 1.9 ± 0.5 | 1.01 | 0.73–1.40 | 0.9 | |||
| Disease duration, years | 3.3 ± 3.1 | 2.6 ± 2.7 | 1.01 | 0.90–1.14 | 0.8 | |||
| Education, years | 7.5 ± 4.8 | 10.5 ± 4.1 | 0.90 | 0.82–0.98 | 0.02 | |||
| Education ≤ 8 years | 21 (75.0) | 22 (42.3) | 1 | / | / | 1 | / | / |
| Education > 8 years | 7 (25.0) | 30 (57.7) | 0.35 | 0.15–0.82 | 0.02 | 0.37 | 0.15–0.89 | 0.03 |
| LED mg/day | 480.8 ± 569.5 | 425.0 ± 415.6 | 1.00 | 0.99–1.00 | 0.5 | |||
| Depression | 13 (46.4) | 45 (31.8) | 1.80 | 0.83–3.88 | 0.1 | |||
| Phenotype | ||||||||
| TD | 11 (39.3) | 19 (42.2) | 1 | |||||
| PIGD | 15 (53.6) | 24 (53.3) | 0.75 | 0.34–1.65 | 0.5 | |||
| Mixed | 2 (7.1) | 2 (4.4) | 3.50 | 0.72–16.9 | 0.1 | |||
Cox proportional-hazards regression models. PD: Parkinson’s Disease; PD-NC: PD with Normal Cognition; PD-MCI: PD with Mild Cognitive Impairment; HR: Hazard Ratio; UPDRS-ME: Unified Parkinson’s Disease Rating Scale Motor Examination; HY: Hoehn and Yahr; LED: Levodopa Equivalent Daily Dose; TD: Tremor Dominant; PIGD: Postural Instability Gait Difficulty.